A study has found that aficamten is associated with improvements across a range of clinical outcomes in patients with obstructive hypertrophic cardiomyopathy.
BACKGROUND: Patients with hypertrophic cardiomyopathy without left ventricular outflow tract obstruction commonly experience ...
Medpage Today on MSN4d
Inching Toward a Blood Test for Hypertrophic CardiomyopathyHCM is a relatively common genetic cardiomyopathy that can be a challenge to diagnose, with about one in three patients misdiagnosed as having another cardiomyopathy. Genetic testing identifies a ...
Rolling Submission of NDA for Aficamten Completed and Submitted to FDA in Q3 COMET-HF, Confirmatory Phase 3 Clinical Trial of ...
A new AI-enhanced ... and quality of life. Medications known as cardiac myosin inhibitors (CMIs) are being developed to help patients with hypertrophic obstructive cardiomyopathy (HOCM), a disease ...
The company is advancing its pipeline with a significant focus on developing treatments for hypertrophic cardiomyopathy and heart failure. In its third-quarter earnings report for 2024, Cytokinetics ...
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced six upcoming presentations at the American Heart Association Scientific ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback